{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:37:46Z","timestamp":1789202266797,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejca.2024.114022","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T21:51:47Z","timestamp":1710971507000},"page":"114022","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials"],"prefix":"10.1016","volume":"202","author":[{"given":"Vadim","family":"Lesan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timoth\u00e9e","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114022_bib1","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejca.2020.09.031","article-title":"Censored patients in Kaplan-Meier plots of cancer drugs: an empirical analysis of data sharing","volume":"141","author":"Rosen","year":"2020","journal-title":"Eur J Cancer [Internet]"},{"issue":"16","key":"10.1016\/j.ejca.2024.114022_bib2","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1016\/j.ejca.2015.07.005","article-title":"The role of censoring on progression free survival: oncologist discretion advised","volume":"51","author":"Prasad","year":"2015","journal-title":"Eur J Cancer [Internet]"},{"key":"10.1016\/j.ejca.2024.114022_bib3","doi-asserted-by":"crossref","unstructured":"Wang M., Jurczak W., Trn\u011bn\u00fd M., Belada D., Wrobel T., Ghosh N., et al. Ibrutinib Combined with Venetoclax in Patients with Relapsed\/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study. In [cited 2024 Jan 8]. Available from: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper191921.html.","DOI":"10.1182\/blood-2023-191921"},{"issue":"7","key":"10.1016\/j.ejca.2024.114022_bib4","article-title":"The frequency of assessment of progression in randomized oncology clinical trials","volume":"5","author":"Haslam","year":"2022","journal-title":"Cancer Rep (Hoboken) [Internet]"},{"key":"10.1016\/j.ejca.2024.114022_bib5","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejca.2018.11.012","article-title":"A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology","volume":"106","author":"Haslam","year":"2019","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2024.114022_bib6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/jamaoncol.2021.8206","article-title":"Biased evaluation in cancer drug trials\u2014how use of progression-free survival as the primary end point can mislead","volume":"8","author":"Tannock","year":"2022","journal-title":"JAMA Oncol [Internet]"},{"key":"10.1016\/j.ejca.2024.114022_bib7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41571-020-0368-0","article-title":"Informative censoring \u2014 a neglected cause of bias in oncology trials","volume":"17","author":"Templeton","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114022_bib8","doi-asserted-by":"crossref","unstructured":"Baselga J, Campone M, Piccart M, Burris HAI, Rugo HS, Sahmoud T, et al. Everolimus in Postmenopausal Hormone-Receptor\u2013Positive Advanced Breast Cancer. https:\/\/doi.org\/10.1056\/NEJMoa1109653 [Internet]. 2012 Feb 9 [cited 2024 Jan 16];366(6):520\u20139. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/nejmoa1109653.","DOI":"10.1056\/NEJMoa1109653"},{"key":"10.1016\/j.ejca.2024.114022_bib9","unstructured":"FDA Panel Votes Against Quizartinib for AML [Internet]. [cited 2024 Jan 16]. Available from: https:\/\/www.onclive.com\/view\/fda-panel-votes-against-quizartinib-approval-for-aml."},{"key":"10.1016\/j.ejca.2024.114022_bib10","unstructured":"Study Details | A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. | ClinicalTrials.gov [Internet]. [cited 2024 Mar 9]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT03539744?cond=NCT03539744&rank=1."},{"issue":"12","key":"10.1016\/j.ejca.2024.114022_bib11","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med [Internet]"},{"key":"10.1016\/j.ejca.2024.114022_bib12","article-title":"Lutetium-177-PSMA-617 in\u00a0metastatic castration-resistant prostate cancer: limitations of the VISION trial","author":"Olivier","year":"2022","journal-title":"Eur Urol."},{"issue":"7","key":"10.1016\/j.ejca.2024.114022_bib13","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol [Internet]"},{"key":"10.1016\/j.ejca.2024.114022_bib14","unstructured":"FDA\u2019s ODAC Votes No for Sotorasib in KRAS G12C-Mutated NSCLC [Internet]. [cited 2024 Jan 16]. Available from: \u3008https:\/\/www.targetedonc.com\/view\/fda-s-odac-votes-no-for-sotorasib-in-kras-g12c-mutated-nsclc\u3009."},{"issue":"6","key":"10.1016\/j.ejca.2024.114022_bib15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/jnci\/djk091","article-title":"When you look matters: the effect of assessment schedule on progression-free survival","volume":"99","author":"Panageas","year":"2007","journal-title":"JNCI: J Natl Cancer Inst [Internet]"},{"issue":"16","key":"10.1016\/j.ejca.2024.114022_bib16","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2005.05.112","article-title":"Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial","volume":"23","author":"Kabbinavar","year":"2005","journal-title":"J Clin Oncol [Internet]"},{"issue":"4","key":"10.1016\/j.ejca.2024.114022_bib17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA - mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med [Internet]"},{"issue":"5","key":"10.1016\/j.ejca.2024.114022_bib18","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamainternmed.2018.8351","article-title":"Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials","volume":"179","author":"Chen","year":"2019","journal-title":"JAMA Intern Med [Internet]"},{"key":"10.1016\/j.ejca.2024.114022_bib19","doi-asserted-by":"crossref","unstructured":"Longo D.L., Drazen J.M. Data Sharing. https:\/\/doi.org\/101056\/NEJMe1516564 [Internet]. 2016 Jan 21 [cited 2024 Jan 18];374(3):276\u20137. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMe1516564.","DOI":"10.1056\/NEJMe1516564"},{"issue":"10","key":"10.1016\/j.ejca.2024.114022_bib20","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1158\/1078-0432.CCR-12-2934","article-title":"Overview: progression-free survival as an endpoint in clinical trials with solid tumors","volume":"19","author":"Korn","year":"2013","journal-title":"Clin Cancer Res [Internet]"},{"issue":"6","key":"10.1016\/j.ejca.2024.114022_bib21","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.jval.2023.03.2294","article-title":"Relationship between Overall Response Rate (ORR), Progression-Free Survival (PFS), and Overall Survival (OS) in Clinical Trials of Patients with Mantle Cell Lymphoma (MCL)","volume":"26","author":"Jen","year":"2023","journal-title":"Value Health [Internet]"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924006786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924006786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T04:10:33Z","timestamp":1727410233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924006786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":21,"alternative-id":["S0959804924006786"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114022","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"114022"}}